Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $2.5 million.

  • Ascendis Pharma A's Cash from Operations rose 10408.31% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year increase of 5981.75%. This contributed to the annual value of -$331.4 million for FY2024, which is 3409.42% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash from Operations of $2.5 million as of Q3 2025, which was up 10408.31% from -$8.3 million recorded in Q2 2025.
  • Ascendis Pharma A's Cash from Operations' 5-year high stood at $2.5 million during Q3 2025, with a 5-year trough of -$166.7 million in Q2 2023.
  • Over the past 5 years, Ascendis Pharma A's median Cash from Operations value was -$110.4 million (recorded in 2024), while the average stood at -$98.8 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 12249.03% in 2021, then surged by 10408.31% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Cash from Operations stood at -$143.4 million in 2021, then decreased by 0.83% to -$144.6 million in 2022, then skyrocketed by 68.39% to -$45.7 million in 2023, then crashed by 103.86% to -$93.2 million in 2024, then skyrocketed by 102.7% to $2.5 million in 2025.
  • Its Cash from Operations was $2.5 million in Q3 2025, compared to -$8.3 million in Q2 2025 and -$15.1 million in Q1 2025.